Elsevier

Medicina Clínica

Volume 129, Issue 12, October 2007, Pages 458-468
Medicina Clínica

Artículo especial
Medidas de seguridad viral del plasma destinado a transfusión y su aplicación en España

https://doi.org/10.1157/13111004Get rights and content

First page preview

First page preview
Click to open first page preview

Referencias bibliográficas (78)

  • S. Wollowitz

    Fundamentals of the psoralene-based HelinxTM technology for inactivation of infectious pathogens and leukocytes in platelets and plasma

    Semin Hematol

    (2001)
  • V. Ciaravino

    Preclinical safety of a nucleid acid-targeted HelinxTM compound: a clinical perspective

    Semin Hematol

    (2001)
  • D. Van Rhenen et al.

    Transfusion of pooled buffy coat platelet components with photochemical pathogen inactivation treatment: the euroSPRITE trial

    Blood

    (2003)
  • P.D. Mintz et al.

    Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

    Blood

    (2006)
  • R.P. Goodrich et al.

    The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends

    Transfus Apher Sci

    (2006)
  • M.P. Busch et al.

    Current and emerging infectious risk of blood transfusions

    JAMA

    (2003)
  • M. Álvarez et al.

    Residual risk of transfusion-transmited vírica infections in Spain, 1997-2002, and impact of nucleic acid testing

    Euro Surveill

    (2005)
  • Ministerio de Sanidad y Consumo. Estadística Estatal de Centros de Transfusión [documento electrónico] [citado Dic...
  • J.P. Wallis et al.

    Long-term survival after blood transfusion: a population based study in the North of England

    Transfusion

    (2004)
  • A. Pereira et al.

    A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

    Transfusion

    (2000)
  • A. Pereira

    Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union

    Transfusion

    (2003)
  • Ministerio de Sanidad y Consumo. Vigilancia epidemiológica del VIH en España: actualización año 2005 [documento...
  • A. Pereira

    Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

    Transfusion

    (1999)
  • B.R. Jackson et al.

    Update of cost-effectiveness analysis for solvent-detergent-treated plasma [carta]

    JAMA

    (1999)
  • P. Hellstern

    Solvent/detergent-treated plasma: composition, efficacy, and safety

    Curr Opin Hematol

    (2004)
  • Coignard BP, Nguyên G, Tokars J, McMillan M, Mascola L, Jarvis W. A cluster of intra-operative deaths in a liver...
  • FDA. 2002 safety alerts for drugs, biologicals, medical devices, and dietary supplements. MedWatch [Documento...
  • Gradis D. Doctors are cautioned not to give a type of plasma to liver patients. The New York Times, 11 de mayo de...
  • P. Hellstern et al.

    Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients

    Infusionsther Transfusionsmed

    (1993)
  • A. Inbal et al.

    Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and aacquired coagulation disorders

    Blood Coagul Fibrinolysis

    (1993)
  • M.S. Horowitz et al.

    SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available

    Vox Sang

    (1998)
  • L.M. Williamson et al.

    A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation

    Transfusion

    (1999)
  • K.H. Beck et al.

    Comparison of solvent/detergent-inactivated plasma and fresh frozenplasma under routine clinical conditions

    Infusionsther Transfusionsmed

    (2000)
  • R.G. Lerner et al.

    Evaluation of solvent/detergent plasma in patients with prolonged prothrombin time

    Vox Sang

    (2000)
  • H. Haubelt et al.

    Effects of solvent/detergent-treated plasma and fresh frozen plasma on hemostasis and fibrinolysis in complex coagulopathy following open-heart surgery

    Vox Sang

    (2002)
  • J. De Jonge et al.

    Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®)

    Anesth Analg

    (2002)
  • S. Tollofsrud et al.

    Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery

    Intensive Care Med

    (2003)
  • E. Santagostino et al.

    Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: doping, pharmacokinetics and clinical efficacy

    Haematologica

    (2006)
  • V. Chekrizova et al.

    Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies

    Transfus Med

    (2006)
  • Cited by (3)

    • The cryoprecipitate: That old unknown

      2015, Revista Espanola de Anestesiologia y Reanimacion
    View full text